Incyte Corp (INCY)

Incyte (INCY) Stock Price & Analysis


INCY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$65.07 - $86.29
Previous Close$84.36
Average Volume (3M)1.46M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$2.98B
Total Debt (Recent Filing)$42.08M
Price to Earnings (P/E)21.4
Next EarningsMay 02, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)3.94
Shares Outstanding222,475,468
Standard Deviation0.09
10 Day Avg. Volume1,433,795
30 Day Avg. Volume1,462,083
Price to Book (P/B)4.81
Price to Sales (P/S)7.72
Price to Cash Flow (P/CF)23.70
P/FCF Ratio30.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside12.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was $65.07 and its highest was $86.29 in the past 12 months.
    What is Incyte’s market cap?
    Currently, no data Available
    When is Incyte’s upcoming earnings report date?
    Incyte’s upcoming earnings report date is May 02, 2023 which is in 83 days.
      How were Incyte’s earnings last quarter?
      Incyte released its earnings results on Feb 07, 2023. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.3 by -$0.17.
        Is Incyte overvalued?
        According to Wall Street analysts Incyte’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Incyte pay dividends?
          Incyte does not currently pay dividends.
          What is Incyte’s EPS estimate?
          Incyte’s EPS estimate is $0.5.
            How many shares outstanding does Incyte have?
            Incyte has 222,475,460 shares outstanding.
              What happened to Incyte’s price movement after its last earnings report?
              Incyte reported an EPS of $0.13 in its last earnings report, missing expectations of $0.3. Following the earnings report the stock price went up 3.511%.
                Which hedge fund is a major shareholder of Incyte?
                Among the largest hedge funds holding Incyte’s share is Dodge & Cox. It holds Incyte’s shares valued at 1B.


                  Incyte Stock Smart Score

                  The Incyte stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Incyte Corp

                  Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Alnylam Pharma
                  BioMarin Pharmaceutical

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis